Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multipl...
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
25 Sep 2019
Treatment options for high risk relapsed/refractory multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
25 Sep 2019
BCMA: A new biomarker for multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
25 Sep 2019
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multip...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
25 Sep 2019
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/re...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
25 Sep 2019
Transitioning from bortezomib to ixazomib in patients with multiple myeloma
Dr Habte Yimer - Texas Oncology, Tyler, USA
23 Sep 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
24 Jun 2019
Chemoimmunotherapy or BTK inhibition for patients with CLL
Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany
20 Jun 2019
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
20 Jun 2019
Blinatumomab for relapsed/refractory Burkitt's lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
20 Jun 2019
Using bioinformatics and genomics to treat AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
20 Jun 2019
The changing landscape of AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
20 Jun 2019
